・"Ultibro Breezhaler (USD 106 million, +4% cc)" a LABA/LAMA, continued to grow, driven by positive
・FLAME, FLASH, and CLAIM study results as well as the GOLD Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease 2018 Report.
・"Seebri Breezhaler (USD 38 million, -4% cc)" an inhaled LAMA, declined, due in part to a focus of resources on Ultibro Breezhaler.
Results from ongoing trials and other highlights (in Q1):
・Ultibro Breezhaler showed significant improvements in cardiac and lung function in COPD patients with lung hyperinflation, compared to placebo.
・The CLAIM study data was published in the Lancet Respiratory Medicine.
